Spyre Therapeutics, Inc (SYRE)
NASDAQ:SYRE
Want to see SYRE full AI Analyst Report?
SYRE Stock Chart & Stats
$73.01
-$0.27(-1.11%)
At close: 4:00 PM EST
$73.01
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$13.93 - $79.54
Previous CloseN/A
Volume84.75K
Average Volume (3M)1.06M
Market Cap
$6.40B
Enterprise Value$4.34B
Total Cash (Recent Filing)$741.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Aug 06, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding86,841,255
10 Day Avg. Volume916,907
30 Day Avg. Volume1,063,690
Financial Highlights & Ratios
PEG Ratio1.94
Price to Book (P/B)15.85
Price to Sales (P/S)0.00
P/FCF Ratio-66.98
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue47.98
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.57
Forecast
1Y Price Target
$95.86Price Target Upside31.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA zero-debt, equity-heavy balance sheet provides durable financial flexibility for a clinical-stage biotech. With low leverage the company can fund multi-year R&D programs, negotiate partnerships from a position of strength, and withstand trial timelines without immediate refinancing pressure.
Recent Capital RaiseA sizable $463.5M financing materially extends runway for pivotal studies, manufacturing scale-up, and combo development. This reduces near-term dilution risk tied to emergency fundraising and enables multi-cohort Phase 2/3 planning, supporting program continuity and strategic optionality.
Positive Phase 2 SKYLINE DataRobust Part A outcomes de-risk SPY001 development structurally: statistical primary endpoint attainment, clinically meaningful remission, and tolerability support a potential best-in-class positioning. Positive wave 2/combination readouts could underpin late-stage programs and licensing interest.
Bears Say
High Cash BurnSustained negative operating and free cash flow near -$185M annually is a structural constraint for a pre-revenue biotech. Even with recent capital, persistent burn necessitates disciplined prioritization of trials, potential future financings, and may pressure timelines or force program trade-offs if clinical costs rise.
Ongoing Net LossesMaterial and recurring net losses indicate the company remains in an investment phase with no path to near-term profitability. This structural loss profile means long-term shareholder returns depend on successful clinical outcomes or partnering, increasing binary outcome risk for investors.
SPY003 Dosing RestrictionsThe license amendment broadens rights but embeds multi-year dosing constraints that limit near-term expansion of SPY003 into non-IBD indications. These contractual limits delay commercialization pathways and combination trial strategies, constraining addressable market capture and partner deal timing.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics, Inc’s price range in the past 12 months?
Spyre Therapeutics, Inc lowest stock price was $13.93 and its highest was $79.54 in the past 12 months.
What is Spyre Therapeutics, Inc’s market cap?
Spyre Therapeutics, Inc’s market cap is $6.40B.
When is Spyre Therapeutics, Inc’s upcoming earnings report date?
Spyre Therapeutics, Inc’s upcoming earnings report date is Aug 06, 2026 which is in 59 days.
How were Spyre Therapeutics, Inc’s earnings last quarter?
Spyre Therapeutics, Inc released its earnings results on May 05, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.666 by -$0.074.
Is Spyre Therapeutics, Inc overvalued?
According to Wall Street analysts Spyre Therapeutics, Inc’s price is currently Undervalued.
Does Spyre Therapeutics, Inc pay dividends?
Spyre Therapeutics, Inc does not currently pay dividends.
What is Spyre Therapeutics, Inc’s EPS estimate?
Spyre Therapeutics, Inc’s EPS estimate is -0.73.
How many shares outstanding does Spyre Therapeutics, Inc have?
Spyre Therapeutics, Inc has 86,841,255 shares outstanding.
What happened to Spyre Therapeutics, Inc’s price movement after its last earnings report?
Spyre Therapeutics, Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.666. Following the earnings report the stock price went up 2.72%.
Which hedge fund is a major shareholder of Spyre Therapeutics, Inc?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.86 (31.29% Upside)
$95.86 (31.29% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 296.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Bullish
Bullish news 79%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
343.14%
12-Months-Change
Fundamentals
Return on Equity
-31.25%
Trailing 12-Months
Asset Growth
34.08%
Trailing 12-Months
Company Description
Spyre Therapeutics, Inc
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$95.86
▲(31.29% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
6.50% Insiders
22.60% Mutual Funds
48.95% Other Institutional Investors
10.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---